Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of TAK 831 in Healthy Adult Asian Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2018
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Friedreich's ataxia; Schizophrenia
- Focus Adverse reactions
- Sponsors Takeda
- 05 Nov 2018 Last checked against Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 30 Oct 2018 Planned number of patients changed from 32 to 40.
- 30 Oct 2018 Status changed from not yet recruiting to recruiting.